Zymosense Inc.
Ames, IA
- UEI
- NLLSAWVUE3M7
- CAGE
- 8V1W4
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 2233 McKinley Ct, Ames, IA 50010, USA
- Website
- zymosense.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Mirimus, Inc. | NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Dotquant LLC | Shoreline, WA | — |
| Endomimetics, Inc. | Birmingham, AL | — |
| Attogene Corporation | Austin, TX | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Benanova Inc. | Cary, NC | 541713 Research and Development in Nanotechnology |
About the company
Zymosense Inc. is a biotechnology research company that specializes in developing innovative solutions for various industries. With a focus on biotechnology, Zymosense aims to revolutionize the way we approach research and development. Zymosense was registered in SAM.gov on January 26, 2021, with its registration set to expire on July 22, 2024. It is structured as a corporate entity (not tax-exempt) and is self-certified as a small disadvantaged business and for-profit organization.
Zymosense Inc. has received several federal grant awards to support its research and development activities. The National Institute of Standards and Technology awarded Zymosense an $800,000 Cooperative Agreement under the Science, Technology, Business and/or Education Outreach program (CFDA 11.620) from September 1, 2022, through August 31, 2024. This award aims to optimize Zymosense's automated pipetting screening tool for assessing single-walled carbon nanotube dispersion and separation processes, with the goal of developing an additive SWCNT purification method for commercial applications. The company also received a $256,000 Project Grant from the National Science Foundation Division of Industrial Innovation on December 1, 2021, under the Engineering program (CFDA 47.041) to develop a platform for rapid assessment of hydrolytic enzyme activity to optimize their design and use. Additionally, Zymosense received a $100,000 Cooperative Agreement from the National Institute of Standards and Technology's Science, Technology, Business and/or Education Outreach program (CFDA 11.620) from August 1, 2021, through March 31, 2022, for automated aqueous two-phase extraction for low-cost and scalable sorting of chiral-pure single-walled carbon nanotubes. Zymosense also intends to provide a subaward to the University of Iowa to receive training in machine learning and Bayesian optimization techniques to enhance its screening tool.
Quick answers
Is Zymosense Inc. registered in SAM.gov?
Zymosense Inc.'s SAM.gov registration expired on August 21, 2026.
What is Zymosense Inc.'s most recent federal award?
Zymosense Inc.'s most recent federal grant award is Phase i NIST sbir project, zymosense built and demonstrated feasibility of a screening tool that uses an automated… (70NANB22H133), from National Institute of Standards and Technology, on September 1, 2022.
On GovTribe
See Zymosense Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors